The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Nobody likes sweaty feet. Not on ourselves, not on our partners, not on anyone close to us, in physical distance and in ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI reading of 26.7, after changing hands as low as $21.89 per share.

State officials' apparent contradictory statements leave Fairhope officials searching for answers about sudden loss of ...

The Alabama Public Library Service (APLS) voted to pause $40,000 in funding to the Fairhope Public Library after the ...

The National Population Commission (NPC) has called for increased collaboration among stakeholders to tackle Nigeria’s ...

Wahl provided a federal definition of "sexually explicit conduct" that doesn't appear to apply to written content.

They also criticized the Alabama Public Library Services (APLS) board and its chairman, John Wahl, for stating in February ...

The library board meets April 21 and will consider Wahl’s request to initiate a review of the books.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...